Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 2/20 | 0.59 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158620 | 1.00 | PLA2G1B (0.59) | PLA2G1BATG4BIDO1LMNATP53 | |
| Hydrochloric Acid SCHEMBL27636314 | 0.98 | PLA2G1B (0.57) | PLA2G1BATG4BIDO1LMNATP53 | |
| Sulfuric Acid SCHEMBL11883310 | 0.91 | CA1 (0.50) | PLA2G1BATG4BIDO1LMNATP53 | |
| SCHEMBL3672272 | 0.89 | CYP2C9 (0.48) | PLA2G1BATG4BHPGDALDH1A1POLB | |
| Trifluoroacetic Acid SCHEMBL5447693 | 0.87 | HTT (0.50) | PLA2G1BATG4BLMNATP53HTT | |
| SCHEMBL17777347 | 0.85 | PLA2G1B (0.52) | PLA2G1BATG4BIDO1LMNATP53 | |
| Hydrochloric Acid SCHEMBL19371473 | 0.83 | PLA2G1B (0.50) | PLA2G1BATG4BIDO1LMNATP53 | |
| SCHEMBL14686209 | 0.81 | TPSAB1 (0.59) | TSHR | |
| SCHEMBL6881703 | 0.81 | CYP2C9 (0.42) | PLA2G1BATG4BPOLBKMT2A | |
| SCHEMBL6881708 | 0.81 | EPHX2 (0.45) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350192-A | Phenoxyalkyl guanidine derivative of targeting norepinephrine transporter as well as preparation method and application thereof | 四川大学华西医院 | 2025-01-24 | — | — | CN | disclosed |
| US-11241509-B2 | Ligands for imaging cardiac innervation | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-2948188-B1 | NEURONAL IMAGING AND TREATMENT | TYLERTON INT HOLDINGS INC (VG) | 2021-09-08 | — | — | EP | disclosed |
| EP-3567029-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-2753605-B1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20150366523-A1 | NEURONAL IMAGING AND TREATMENT | TYLERTON INTERNATIONAL HOLDINGS INC. (VG) | 2015-12-24 | — | — | US | disclosed |
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013036869-A2 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2008083056-A2 | LIGANDS FOR IMAGING CARDIAC INNERVATION | LANTHEUS MEDICAL IMAGING, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-0944599-A1 | TRIARYLETHANES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998028276-A1 | TRIARYLETHANES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
| US-3714364-A | PROCESS FOR LOWERING BLOOD SUGAR LEVELS | PFIZER | 1973-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | PLA2G1B 1857/4885ATG4B 1544/4885IDO1 3282/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | PLA2G1B 1857/4885ATG4B 1544/4885IDO1 3282/4885 |
| US-11241509-B2 | Ligands for imaging cardiac innervation | TNNT2, PNMT, TNNC1 | PLA2G1B 2678/4885ATG4B 4129/4885IDO1 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.